m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04281)
Name
DWP-431
Synonyms
Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D03HDV
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Bone morphogenetic protein 2 (BMP2)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Bone morphogenetic protein 2 (BMP2) is a therapeutic target for DWP-431. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of DWP-431 through regulating the expression of Bone morphogenetic protein 2 (BMP2). [1], [2]
References
Ref 1 BMP2 Modified by the m(6)A Demethylation Enzyme ALKBH5 in the Ossification of the Ligamentum Flavum Through the AKT Signaling Pathway. Calcif Tissue Int. 2020 May;106(5):486-493. doi: 10.1007/s00223-019-00654-6. Epub 2020 Jan 2.
Ref 2 Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. J Med Chem. 2014 Oct 9;57(19):8099-110. doi: 10.1021/jm5010495. Epub 2014 Sep 17.